Clinical Trials Directory

Trials / Completed

CompletedNCT01338831

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
73 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile. Once the MTD has been established and/or a RP2D chosen, the study will enroll patients into the expansion portion of the study.

Conditions

Interventions

TypeNameDescription
DRUGLFA102

Timeline

Start date
2011-09-01
Primary completion
2014-03-01
Completion
2014-03-01
First posted
2011-04-20
Last updated
2020-12-17

Locations

9 sites across 4 countries: United States, Belgium, Italy, Spain

Source: ClinicalTrials.gov record NCT01338831. Inclusion in this directory is not an endorsement.